Kairos Pharma (KAPA) shares were down 14% in recent Tuesday trading after the company said it received approval to dual list its stock on Upstream, a global trading app for digital securities.
With the dual listing, the company said it can access a global investor base outside the US for additional liquidity and price discovery enhancement.
The Upstream platform facilitates real-time trading and settlement, and ensures a transparent orderbook that does not allow common market manipulations, Kairos said.
Price: 1.43, Change: -0.28, Percent Change: -16.37
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。